ArticleThrombosis journal2026
Thrombosis biomarkers: utility in early diagnosis and prognosis of severe pneumonia.
Article in Thrombosis journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundPneumonia is a major health problem and the most important causes of mortality in all age groups worldwide. We investigated new automation technology to detect plasma biomarkers, including thrombinantithrombin complex (TAT), α2-plasmininhibitor-plasmin complex (PIC), soluble thrombomodulin (sTM), and tissue plasminogen activator-inhibitor complex (t-PAI·C), and evaluated their diagnostic performance and prognostic value for severe pneumonia patients.
methodsWe collected 414 patients date with pneumonia. sTM, t-PAI·C, TAT, PIC were measured by qualitative chemiluminescence immunoassay performed on HISCL analyzers. Other laboratory tests were evaluated on the day of non-severe pneumonia and severe pneumonia diagnosis.
resultsThere were significant differences in sTM, t-PAI·C, TAT, PIC (p < 0.0001), WBC (p = 0.023), PCT (p = 0.007) and IL-6 (p = 0.002) between the severe pneumonia and non-severe pneumonia groups, Logistic regression analysis showed that sTM (p = 0.001), t-PAI·C (p = 0.001), TAT (p = 0.022), PIC (p = 0.000) and APTT (p = 0.013) were independent risk factors for severe pneumonia. Logistic regression analysis showed that t-PAI·C (p = 0.006) was an independent risk factor for hospital mortality in severe pneumonia. The AUC of sTM combined with t-PAI·C, TAT and PIC on diagnosis of patients with severe pneumonia was 0.868 (95% CI: 0.837, 0.899). Kaplan-Meier survival analysis with a log-rank test showed the in-hospital death rate of severe pneumonia was higher in the high TAT (≥ 5.58ng/mL) level than in group with low TAT (< 5.58ng/mL) level (log rank < 0.029). The same trend with high t-PAI·C was also found in severe pneumonia patients (log rank < 0.021).
conclusionsThe thrombosis markers are helpful for the diagnosis and prognostic assessment of severe pneumonia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.